<p><strong>ER+/ HER2 -ve Breast Cancer</strong></p>
<p>Breast cancer that is ER positive or PR-positive falls under the category of hormone receptor-positive (HR+) breast cancer. Additionally, there is another category of breast cancer which is known as hormone receptor-negative (HR). This type of breast cancer has cells without hormone receptors. HR- breast cancer cells do not depend on estrogen or progesterone to grow.</p>
<p>In addition, another factor is also responsible for breast cancer, which is known as the human epidermal growth factor receptor 2 (HER2). Human epidermal growth factor receptor-2 is a gene that helps control how cells grow, divide, and repair themselves. These proteins are receptors on breast cells. Human epidermal growth factor receptor-2 positive (HER2+) is breast cancer that tests positive for the HER2 protein</p>
<h2><strong>ER+/ HER2 -ve Breast Cancer Epidemiology Segmentation in the 7MM</strong></h2>
<ul>
<li>Total incident cases of breast cancer</li>
<li>Total Incident Cases of HER2-negative Breast Cancer</li>
<li>Stage-specific Incident Cases of HER2-negative Breast Cancer</li>
<li>Treatable Cases of HER2-negative Breast Cancer</li>
</ul>
<p>&nbsp;</p>
<h3><strong>ER+/ HER2 -ve Breast Cancer Epidemiological Insights Observed in the 7MM (2021)</strong></h3>
<p>The total number of incident cases of ER+/ HER2 -ve Breast Cancer observed in the United Stated were observed to be <strong>256,000 in the year 2021</strong></p>
<h2><a href="https://www.delveinsight.com/report-store/er-her2-ve-breast-cancer-market"><span style="text-decoration: underline;"><strong>ER+/ HER2 -ve Breast Cancer Market Insight</strong></span></a></h2>
<p>The ER+/ HER2 -ve Breast Cancer Market size was approximately <strong>USD 6,759 Million </strong>in the United States in the year 2021.&nbsp;</p>
<p>&nbsp;</p>
<h3><a href="https://www.delveinsight.com/report-store/er-her2-ve-breast-cancer-pipeline-insight"><span style="text-decoration: underline;"><strong>ER+/ HER2 -ve Breast Cancer Emerging Drugs</strong></span></a></h3>
<p>The emerging drugs in the ER+/ HER2 -ve Breast Cancer market are</p>
<ul>
<li>Elacestrant (RAD1901)</li>
<li>Amcenestrant (SAR439859)</li>
<li>Giredestrant (RG6171, GDC-9545)</li>
<li>Camizestrant (AZD9833)</li>
<li>LY3484356/Imlunestrant</li>
<li>Lerociclib</li>
<li>TRODELVY (sacituzumab govitecan)</li>
<li>Capivasertib</li>
<li>Lasofoxifene</li>
<li>SFX-01</li>
<li>SM-88</li>
<li>Inavolisib</li>
<li>Datopotamab deruxtecan (Dato-DXd)</li>
<li>Enobosarm</li>
</ul>
<h3><strong>ER+/ HER2 -ve Breast Cancer Key Players&nbsp;</strong></h3>
<p>The key players working in the ER+/ HER2 -ve Breast Cancer market are</p>
<ul>
<li>Radius Pharmaceuticals</li>
<li>Sanofi</li>
<li>Roche</li>
<li>AstraZeneca</li>
<li>Eli Lilly</li>
<li>EQRx</li>
<li>Gilead</li>
<li>AstraZeneca</li>
<li>Sermonix Pharmaceuticals</li>
<li>Evgen Pharma</li>
<li>Tyme</li>
<li>Roche/ Genentech</li>
<li>AstraZeneca and Daiichi Sankyo</li>
<li>Veru</li>
</ul>

ER+/ HER2 -ve Breast Cancer Market

ER+/ HER2 -ve Breast Cancer Market Infographics

 ER+/ HER2 -ve Breast Cancer Symptoms, Treatment, epidemiology, companies, drugs, infographic is a short guide to understand the problem and market landscape